Indian contract drug manufacturers reported stronger growth in the June quarter, driven by demand for complex medicines and supply chain shifts. However, performance remains split, with industry leaders like Divi’s Laboratories and Laurus Labs outpacing peers, while others face contract losses and execution hurdles. This divergence highlights the importance of client stability and technical capabilities in evaluating these stocks.
The Indian contract research, development, and manufacturing organization (CDMO) sector—companies that help global pharmaceutical firms research and produce drugs—saw a rebound in the June quarter (Q1 FY27). Industry-wide data suggests a revenue increase of nearly 19% year-on-year for major players, marking a recovery from the single-digit growth seen in the previous quarter.
However, this growth is not uniform. The sector's performance has split into two groups. High-performing companies such as Divi’s Laboratories and Laurus Labs have capitalized on global demand for specialized medicines. Divi’s Laboratories, for instance, reported a significant revenue jump of 27.8% and profit growth of 65.5% for the June quarter. Similarly, Laurus Labs saw its CDMO segment revenue rise by approximately 70% compared to the previous year, leading the management to increase spending on expansion.
In contrast, some players are facing operational headwinds. Syngene International, for example, reported a 16% revenue decline in the same period, citing the loss of a key contract and pressure from foreign exchange volatility. This performance gap highlights that while the overall industry is benefiting from the ‘China+1’ strategy—where global pharma companies move manufacturing away from China to diversify their supply chains—individual success depends heavily on specific client relationships and technical capabilities.
Companies that focus on high-value, complex areas like peptides, antibody-drug conjugates (ADCs), and specialized chemicals are finding more success. These advanced drug classes are currently in high demand as global pharma companies seek partners capable of handling complex manufacturing processes that require strict quality controls.
Investors should be aware that the sector faces specific risks that can cause results to fluctuate. One major risk is client concentration. As seen with recent results, the loss of a single large contract can significantly impact a company's revenue. Additionally, the sector is sensitive to the funding cycles of biotech companies. When funding slows, these smaller biotech firms—which often outsource their early-stage research to Indian CDMOs—may delay projects, leading to order deferrals.
Furthermore, regulatory quality standards remain a constant monitorable. Indian firms are increasingly under the scrutiny of global regulators like the USFDA and EMA. Any failure to meet these evolving quality benchmarks can lead to import alerts or loss of credibility, which are difficult to reverse. Other factors such as currency fluctuations, which impacted the margins of several firms this quarter, and the ability to maintain profitability amidst intense global competition are also critical.
The next steps for investors to track include order book execution, as companies with high order visibility are better protected against near-term demand fluctuations. Monitoring management commentary on client retention and the stability of biotech funding will also be essential for understanding whether the current performance gap between industry leaders and peers will widen or narrow in the coming quarters.